Author Guidelines

1.1 Essential Information

- Articles must be submitted to the journal's online peer review system.

- An anonymous version of your article should be submitted along with a separate title page.

All authors, their affiliations and ORCIDs should be included on a separate title page. Please see a template for the title page here.

- All article types (excluding invited editorials and letters to the editor) must include an abstract and keywords (max 7).

Articles must be submitted in Word.doc format and set up with continuous line numbering, double line spacing and page numbers.

- Figures and tables:

  • 1. No more than 5 figures and tables in total.
  • 2. Additional figures/ tables, and those that fill more than 2 pages, should be marked as supplementary material.
  • 3. Should appear at the end of the article, not embedded in the text.
  • 4. Must include a figure/table title of no more than 100 characters.
  • 5. Each figure/table must be referred to within the manuscript
  • 6. Figures uploaded as image files
  • 7. Any videos must be supplied as a URL link only.

- References:

  • 1. Must be cited within the text body and appear in numerical order of first mention.
  • 2. List the first three authors only, followed by et al., unless there are four authors, in which case list all four.
  • 3. Must include DOI and PubMed ID.

- AER and JAPSC only: For all original research, review articles and case reports, authors must include a (bulleted) ‘Clinical Perspectives’ statement.

- Original Research articles must include:

  • 1. Background
  • 2. Methods
  • 3. Results
  • 4. Discussion
  • 5. Study limitations
  • 6. Conclusion
  • 7. Trial Registration
  • 8. Data availability statement

- Original Research and Case Reports must include a statement that written informed consent was obtained if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed.

From 01 April 2022, Original Research must include a Data Access Statement even where there are no data associated with the article or the data are inaccessible. Please choose an appropriate statement to accompany your submission.

- Word limits:

Article Type Abstract Word Limit (words) References
Case Report 50 words (unstructured) 1,500 - 3,000  Max 50 refs
Editorial (invited only) N/A 1,500 - 2,000  Max 15 refs
Expert Opinion 120 - 160 words (unstructured) 1,500 - 2,500  Max 20 refs
Letter to Editor N/A Up to 1,500  Max 10 refs
Original Research 250 words (structured) 2,500 - 5,000  Max 100 refs
Review Article 12 - 160 words (unstructured) 2,500 - 5,000  Max 80 refs


- Authors must accept the OA T&Cs in the submission questionnaire.

- Non-native English? Make sure you have considered a language edit prior to submission.

1.2 Summary

The Journal of Asian Pacific Society of Cardiology (JAPSC) endeavours to publish unbiased content. All articles must be of an impartial nature.
 

All submissions are assessed by the editor-in-chief with the support of the deputy and associate editors, and guidance from the editorial board.


Following submission, articles are subject to independent double-blind peer review and copy-editing prior to publication. All articles must receive final approval of the editor-in-chief and/or deputy editors before they are published.


Articles must be submitted using our electronic peer review system, Editorial Manager. Please submit here.

If you are interested in submitting a manuscript and wish to discuss it further, or have any editorial queries, please email the editorial contact for the relevant journal: 
ashlynne.merrifield@radcliffe-group.com.

1.3 Benefits of Publishing with Us

Radcliffe Cardiology’s journals aim to support the continuous medical education of both specialist and general cardiologists. We publish original research, review articles, expert opinions pieces and case reports written by leading authorities, addressing the most pertinent developments in their field. Our authors benefit from:
 

Open research

All research published in JAPSC is open access which means the version of record (VOR) is freely accessible to everyone across the globe immediately upon publication. As an author you retain all non-commercial rights for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license, allowing users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.


Quality

We are committed to the highest standards of peer review. JAPSC follows a rigorous double-blind peer review process that is conducted independently and treated confidentially. All articles and the peer review comments received are evaluated by the Editor-in-Chief before they make their decision.


Speed

On average, articles submitted to Radcliffe Cardiology journals receive their first decision in 5 weeks of submission, ensuring rapid review whilst maintaining high quality, rigorous peer review.


Visibility

In order to maximise the reach and impact of your research, we are committed to ensuring every article we publish is promoted as widely as possible. Along with open access, which supports increased readership and citations with no barriers to access, our marketing team with their SEO expertise, will ensure your research is visible to the widest possible audience, including marketing through our social and email channels to our global community of 100,000+registered recipients.


Society Partnerships

The Journal of Asian Pacific Society of Cardiology (JAPSC) is the official journal of the Asian Pacific Society of Cardiology. Radcliffe Cardiology publishes the journal on behalf of the society.   

1.4 Authorship Criteria

All authors involved should be listed and are accountable for the content should it be published and must meet the following conditions to be considered an author:
 

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and
  2. Drafting the work or revising it critically for important intellectual content; and
  3. Final approval of the version to be published; and
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


Those meeting the above criteria are eligible to participate in reviewing and drafting the final manuscript. The corresponding author will be responsible for key communication with the publisher. Those not meeting the above criteria should be acknowledged as a contributor in the acknowledgments section rather than an author. The editor is not held responsible for identifying authors on the manuscript. This information must be supplied at submission.

1.5 Submission Types

Articles accepted for publication include the following content types and may be solicited or unsolicited:

Content Type

Description

Keywords

Word limits (excluding references/abstract)

Misc.

Figs

Tables

Videos

Clinical perspectives

Case report

Present novel findings or strategies on a particular topic to aid diagnosis/treatment/management

7

1500

Max. 10 refs

Abstract to be supplied (max 50 words)

300dpi

Max. 5

tif,.pdf or .jpeg format

Editorial

*by invitation only

An article that reflects on a particular issue, event, methodology, innovation or gap in literature.

7

1500

Max. 15 refs

Not subject to peer-review

 

 

300dpi

Max. 5

tif,.pdf or .jpeg format

Expert opinion

Coverage of topical issues in cardiology from expert in field that will be of interest to readers

7

1500 – 2500

Max. 20 refs

Accompanied by an abstract (max 160 words)

300dpi

Max. 5

tif,.pdf or .jpeg format

Letter to editor

Readers are invited to provide comment on articles for the EiC to read/respond.

7

500

Max. 5 refs

Not subject to peer-review

Review article

Summary and critical evaluation of current research in field and impact on current and future practice.

7

2500 – 5000

Max. 80 refs

Accompanied by an abstract (max 160 words)

300dpi

Max. 5

tif,.pdf or .jpeg

Original

Research

Including clinical research, meta-analyses and translational science

7

2500 – 5000

Max. 100 refs

Accompanied by a structured abstract

(max 250 words)

300dpi

Max. 5

tif,.pdf or .jpeg

1.6 Article Preparation: Checklist Summary
Section Requirement
Submission types
  • Case Reports: 1,500 words excl abstract & refs. Max. 10 references.
  • Editorial: 1500 words excl abstract & refs. Max. 15 references. Editorials are by invitation only. 
  • Expert Opinion: 1,500 – 2500 words excl abstract & ref. Max. 20 references
  • Letter: 500 words. Max 5 references.
  • Review Article: 2,500 – 5,000 words excl abstract & ref. Max. 100 references.
  • Original Research: 2,500 – 5,000 words excl abstract & Ref. Max 100 references.
Manuscript
  • Submitted as word document with pages clearly numbered
  • Continuous line numbering
  • Double spacing
  • Page numbers.
Title page Title: of the article (<300 characters);

Short title (<75 characters);

Author(s) information: full name, department, institution and/or organisation, full contact information: email addresses for all authors and a postal correspondence address for the lead author. We also encourage ORCID identification to be listed.

Disclosures: a statement of disclosure/conflicts of interest relevant to the article for each author; form for Disclosure of Potential Conflicts of Interest: www.icmje.org/conflicts-of-interest

Acknowledgements (optional):

Funding (optional): include grant numbers for funders if available. 

Correspondence details: 

Support statements: include equipment, drugs, and /or other support that facilitated conduct of the work

Consent to Participate and Publish (if applicable):

Data Availability Statement (if applicable):

Ethics approval statement (if applicable):

Clinical Trial Registration (for clinical trials only): Provide the registry site and identifier number. 

Keywords: a maximum of 7 keywords to be listed

Word count: should be provided for the article and should not include the abstract.

A downloadable template is available here. 
Abstract

Reviews and Expert Opinions:

Unstructured, unreferenced. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

<160 words

Case Reports:

Unstructured, unreferenced. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

<50 words

Original Research:

Structured including the following headings:

  • Background
  • Methods
  • Results
  • Conclusion
  • Trial Registration
The abstract should present essential data in 5 paragraphs. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables.

< 250 words
Keywords 7
Clinical perspective Summarising the clinical implications of your review in three to five bullet points.
Acknowledgements The author(s) should acknowledge substantive contributions to the article, including assistance, advice, materials and other resources.
Conflicts of interest/disclosures The author(s) should state any conflicts of interest/intellectual property to the article, including any sources of financial support or assistance for work; ensure sponsor names/sponsoring organizations are included and the for-profit interest(s) the sponsor represents, if applicable.

Ensure to highlight if authors had access to the study data.

We make it clear when any research has been funded. If a funded paper, please include the statement: Authors had full access to all data in this study and take full responsibility for the integrity of the data and the accuracy of the data analysis.
Patient and Public Involvement Statement

When reporting patient and public involvement in research, please address the following, tailored as appropriate for the study design reported:

1. Stage in the research process where patients/the public we involved and how.

2. How their priorities, experience and preferences were used to develop and inform the research questions(s) and outcome measures.

3. How they were involved in the design of this study?

4. How they were involved in the recruitment to and conduct of the study?

5. State if they were asked to assess the burden of the intervention and the time required to participate in the research. 

6. How/will they be involved in the dissemination of the study results to participants and relevant wider patient communities (e.g by choosing what information/results to share, when and in what format)?

If patients were not involved, please clearly state this. 

Informed consent Authors should include a statement in the manuscript that written informed consent was obtained if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed. Please see section 1.9 for details of our Informed Consent Policy and sample statements. 
Declaration of Helsinki The authors should state that their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that written informed consent has been obtained from the subjects (or their legally authorised representative). 
Data Availability Statement Include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement. Please see Section 3.0 for full details of our Data Sharing Policy.
Layout

Reviews, Expert Opinions and Case Reports:

Divide the text under headings and subheadings. Keep these short and succinct (max 5 words) and similar in sense and style.

Original Research:

Must include the following headed sections:

  • Introduction - brief description of the background that led to the study, aims and hypothesis (results and conclusion should not be included).
  • Methods - provide details of the study population, describe statistical methods with detail to verify the reported results.
    • Patient and Public Involvement and Data Availability statement to be included (if relevant)
  • Results - Comment on validity and significance of results. Include subheadings, use tables to summarise data when possible. Graphical displays of data must be clear and easy to understand. Avoid graphical forms that distort data/are prone to misinterpretation. 
  • Discussion - What do findings show, why are they interesting, how do they support or challenge existing studies? Discuss any caveats.
    • Study limitations should be included at the end of the discussion.
  • Clinical Perspective - if applicable to content type, include and summarise the clinical implications of your review/research in 2-5 bullet points. 
Language

All articles should be written in UK English, free from jargon, and the writing should be clear and direct. 


All acronyms and abbreviations must be explained in full at first mention.

Figures, tables, illustrations, screenshots and photographs

1. A maximum of five may be included. Anything over this amount should be supplied as supplementary data. In addition, any Tables that require more than 2 pages, must be supplied as supplementary material.

2. Digital files must be supplied as (.tiff, .pdf or .jpeg files) and be at least 300 dpi. Original figures may be redrawn as necessary.

3. Clear and concise titles must be provided, and all symbols and abbreviations used must be defined in a footnote. Detailed captions underneath figs/tables is optional.

4. All figures must be referred to in the main text and numbered sequentially. Figures submitted as supplementary material should start their numbering at 1. 

5. Figure and table legends must be included in the manuscript after the reference section

6. All abbreviations used must be defined and spelt out in full in the caption.

7. High-resolution images to be provided at revision stages if not supplied at submission.

Tables:

8. Graphs and tables must be supplied as editable files formatted as a table in Microsoft Word or Excel.

9. To be added after the reference list.

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Please provide licences with submission.

Videos  Videos may be published in the online article with a still image of the video in the print file/PDF. Videos must be submitted in mp4 or avi format. Please ensure the video is accurately labelled. Any additional videos submitted but not included in the main article may appear as supplementary data.
References

In text: All articles must be fully referenced

References must be numbered in order of first mention. They must be indicated in the text by a superscript number with the full list at the end of the article in numerical/chronological order.

Include the first three authors only, followed by et al., unless there are four authors, in which case list all four. Authors must include DOI and PubMed ID. (PubMed IDs can often be imported simply and quickly using a software such as EndNote which most institutions have access to.)

Examples:
 
Journal article: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.

Book Chapter: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

Supplementary Data

Supplementary material may be submitted to the journal if it is necessary to the integrity and excellent of the manuscript. It may take the form of figures, tables, datasets, videos, slide sets, formulas, podcasts etc. The supplementary material must be submitted at the time of manuscript submission as a separate file and will be published as a pdf file (unless in audio or video format). Supplementary figs/tables should be numbered sequentially starting from 1. and should not follow on numbering from the main manuscript. 

Please note: Supplementary material will be subject to the same peer-review standards as the manuscript but will not be edited by the journal staff. Therefore, please take care to ensure that supplementary content is labelled and presented correctly, that grammar is corrected and that the journal style is followed throughout, especially in the references. Supplementary references must be cited in the main article and referenced at the end of the manuscript/acknowledgements. 

Permissions Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are obtained.
Resources When preparing your manuscript, we recommend you consult the following resources to improve the quality of your submission: 

Systematic reviews and meta-analyses: PRISMA guidelines
Case Reports: the CARE case report guidelines 
Clinical trials: CONSORT 
Human Research: Declaration of Helsinki (2013)
Animal studies: ARRIVE
1.7 Submission Templates

To support your submission, please download and edit the templates below:

Title Page

1.8 Permissions

If a figure, table or illustration has been previously published, please ensure the original source is acknowledged as a figure legend and written permission from the copyright holder is sought. All figures/tables must have one of the below statements if they are not original:
 

If it is data taken from and no permissions are required – Data from: XXX et al. YEAR,RefXXX et al. YEAR,RefXXX et al. YEAR.Ref
If it is reproduced – Source: XXX et al. YEAR.Ref Reproduced with permission from PUBLISHER.
If it is adapted – Source: XXX et al. YEAR.
Ref Adapted with permission from PUBLISHER.


Original images that are the authors own and that have not been published elsewhere, do not require permission. If applicable, please indicate this as a legend in your submission. If all images are original, please include a statement to this effect in the manuscript/at submission.


Our journals are open access. Please ensure that open access reuse permission is sought where possible. If it if not, please highlight this by adding ‘This content is not covered by the Creative Commons license of this publication. To reuse, please contact the rights holder.’
 

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are sought.

1.9 Declarations: Conflict of Interest and Intellectual Property

A conflict of interest exists when an opinion may be influenced or biased by a secondary interest such as financial gain. Conflicts of interest may occur from commercial or financial interests and/or personal relationships, beliefs and or rivalries such as research funding, consultancy services, serving on speakers’ bureaus, travel expenses, appearance fees, the receipt of share options, or direct employment by a commercial entity.

Our publications make it clear where any conflicts of interest occur and inform readers when research has been funded. All authors, peer reviewers, editors and editorial board members must declare any conflicts of interest pertaining to the article when submitting a manuscript. All sources of support for the work where a conflict exists will be publicised. Conversely, please state clearly should there be no conflicts of interest to declare.

Reviewers must declare any conflicts of interest before conducting a peer review of a manuscript. Reviewers should decline to review if a potential conflict of interest is present. Editorial staff employed by Radcliffe Group, editors-in-chief, guest editors and editorial board members, will not handle manuscripts where a potential conflict of interest or competing interest exists and will be excluded from the peer-review process.

Editorial members and guest editors may submit to the Journal and are not given any priority over other manuscript submissions. Articles authored by any in-house Editorial Board members will be treated with the same rigorous peer-review rules and handled avoiding any potential conflicts of interest. Where an author is a guest editor or editorial board member, this must be declared using one of the following statements in the submitted manuscript: [Author initials], is on the [insert journal name] editorial board; this did not influence peer review. For multiple editorial board members: [Author initials], is a/an [insert role] and [Author initials] is on the [insert journal name] editorial board; this did not influence peer review. [unless they have other COIs, in which case these shall be listed and added to the individual COIs]

The authors must complete the questions asked in our electronic submission system (Editorial Manager), which follows the ICMJE recommendations. These answers will be stored, and a disclosure statement will appear on every manuscript published within the journal based on your response. The purpose of this statement is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. For more information and to download a Form for Disclosure of Potential Conflicts of Interest, which can be submitted with your manuscript, please visit https://www.icmje.org/conflicts-of-interest.

Acknowledgements: The author(s) should acknowledge substantive contributions to the article, including receipt of financial assistance, materials and other resources.

Informed consent: Authors must ensure that manuscripts involving human subjects have written informed consent from the individual(s) involved and must ensure they provide consent to be involved in/aware of the planned publication as soon as possible. "Consent" refers to the consent to publish an individual's personal information. You should make sure that the original copy of informed consent is held by the treating institution should any queries be raised in the future. 

Informed consent must be given voluntarily, with free will and under no coercion and bribery of any kind. Authors should include a statement in the manuscript that written informed consent was obtained if experimentation/transplantation with human subjects was conducted. This applies even if the participant is deceased.

The privacy rights of human subjects must always be observed and steps should be taken to anonymise information that can identify a patient. Examples of identifying information include individual case histories, photos, x-rays or genetic phenotypes.

For more information please read the Nuremberg Code and the Belmont Report

The table below provides some template statements that you may use or adapt. You can find further guidance on how to compose this statement on the ICMJE recommendations website.

Type  Template statement: Consent to Participate
For Adults 

Written informed consent was obtained from all individuals included in the study. 

For Children  Written informed consent was obtained from all legal guardians OR
Writte informed consent was obtained from the parents.
For a particular figure The authors affirm that human research participants provided written informed consent for the publication of the images in Figure(s) xx.
Additional statement if identifying information is included Additional written informed consent was obtained from all individual participants for whom identifying information is included in the article. 
Type Template Statement: Consent to Publish 
Consent to Publish 

Patients provided written informed consent regarding publishing their data and photographs.

 

Ethics approval, human and animal rights: If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out following the Code of Ethics of the World Medical Association (Declaration of Helsinki) for research involving humans or the EU Directive 2010/63/EU for animal experiments and/or ARRIVE guidelines for animal research. 

Research Type Template statement: 
Human

This study was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). Approval was granted by the Ethics Committee of [insert name].

Animal

This study was approved by the [insert name] animal ethics committee and was carried out in accordance with the appropriate guidelines. 
Observational Study This is an observational study. The [insert name] Research Committee has confirmed that no ethical approval is required. 
1.10 References

All articles must be fully referenced. References must be numbered in order of the first mention. They must be indicated in the text by a number with the full list at the end of the article in numerical order. They must not be used to promote self-interests.
 

Journal Articles 
Journal abbreviations are used as per Medline. If there are more than three authors, list the first three followed by et al., unless there are four authors, in which case list all four. Details should be ordered as: Surname Initials. Article title. Journal name year;volume:page numbers. doi: [doi number]. PMID: [PMID number].


Example: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.


Book Chapters
Example: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

2.0 Peer Review Process

We operate a double-blind peer-review process. All peer reviews are conducted within the Editorial Manager platform.
 

On submission, items submitted to the journal are assessed by the Editor-in-Chief to assess their suitability for inclusion. Items that fail a technical check are returned to the author at this stage for rectifying and are resubmitted. Manuscripts rejected at this stage are either insufficiently original, scientifically/statistically flawed, poor grammar/English language or deemed unsuitable/more suitable for another journal/outside the journal aims and scope.

The Review Editor, following consultation with the Editor-in-Chief, Deputy Editors and/or a member of the Editorial Board, sends the manuscript for peer review. All peer reviews are conducted independently, treated confidentially and are double-blinded. We require a minimum of two independent peer reviews but will seek a third review where there are conflicting reports. The peer reviewers are selected on the basis of their expertise in the article subject matter and have no conflicts of interest. Peer reviewers are not part of the editorial staff and are independent of the article.


The peer-review feedback is used to critically assess the quality of the article, to assess its suitability for inclusion in the journal and to ensure its credibility of scientific information.


Following review, manuscripts are either accepted without modification, accepted pending modification, or may require further revision, in which case the manuscripts may be returned to the author(s) to incorporate required changes, or may be rejected outright. Not all articles that are revised are subsequently accepted. The Editor-in-Chief reserves the right to accept or reject any proposed amendments. The Editors will not consider papers previously rejected by the journal.


Once the authors have revised a manuscript in accordance with the reviewers’ comments, the manuscript is returned to the reviewers to ensure the revised version meets their quality expectations. Once approved, the manuscript is sent to the Editor-in-Chief for final approval prior to publication. We aim to complete the peer review process with the average time from submission to the first decision within 6 weeks and submission to a final decision within 10 weeks.


It is our aim to ensure authors are notified of any rejection or retraction as soon as possible. An editor can reject an article at any time before publication, including after acceptance if there are concerns over the work. In the event that a journal is no longer published, access to all articles will be available via alternative platforms, such as PubMed Central, ESCI or Scopus.

3.0 Data Sharing Policy

Radcliffe is committed to an open science landscape, removing barriers from the sharing of research and the underlying data. This facilitates openness, transparency and reproducibility of research. All Radcliffe journals are open access, and we encourage our authors to share their research data. Research data refers to the information gathered, reviewed, analysed, generated or created and can be presented in a variety of formats including numerical, descriptive, aural, or visual. We encourage Radcliffe authors to:
 

  1. share your research data in a relevant public data repository, where this does not violate the protection of human subjects or other valid subject privacy concerns.
  2. include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement.
  3. cite the data in your research.


As all of our journals operate under a double-blind peer-review process, if sharing your data, you will need to use a repository that includes an option to preserve your anonymity.


Authors are encouraged to share their data but not required to. The decision to publish will not be affected by whether or not authors share their research data.

3.1 Data Repositories

We advise authors to speak to your institutional librarian, funder or colleagues for guidance on choosing a repository that is relevant to your discipline. Alternatively, some useful resources for searching for a suitable repository are FAIRsharing and re3data.org, which provide a list of certified data repositories. Some general repositories that are not subject-specific include:
 

3.2 Data Availability Statement

As per the ICMJE recommendations data sharing statements should include:
 

  1. whether individual de-identified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer);
  2. what data, in particular, will be shared;
  3. whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.);
  4. when the data will become available and for how long;
  5. by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).


The table below provides some template statements that you may use or adapt. You can find further guidance on how to compose this statement on the ICMJE recommendations website.

In order to be compliant with open access funder policies, from 01 April 2022, original research must include a Data Access Statement, even where there are no data associated with the article or the data are inaccessible. Please choose an appropriate statement from the list below to accompany your submission: 

Availability of Data Template Statement
Data is openly available in a public repository (DOI provided) The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number].
Data openly available in a public repository (no DOI provided) The data that support the findings of this study are openly available in [repository name] at [URL], reference number [reference number].
Data derived from public domain resources The data that support the findings of this study are available in [repository name] at [URL/DOI], reference number [reference number]. These data were derived from the following resources available in the public domain: [list resources and URLs]
Embargo on data due to commercial restrictions The data that support the findings will be available in [repository name] at [URL / DOI link] following an embargo from the date of publication to allow for commercialization of research findings.
Data available on request due to privacy/ethical restrictions The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Data subject to third party restrictions The data that support the findings of this study are available from [third party]. Restrictions apply to the availability of these data, which were used under license for this study. Data are available [from the authors / at URL] with the permission of [third party].
Data available on request from the authors The data that support the findings of this study are available from the corresponding author upon reasonable request.
Data sharing not applicable – no new data generated Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Author elects to not share data Research data are not shared.
Data available in article supplementary material The data that supports the findings of this study are available in the supplementary material of this article.
Data sharing not applicable – no new data generated, or the article describes entirely theoretical research Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
3.3 Data Citation

Radcliffe supports the Force 11 Data Citation Principles, as such all publicly available datasets must be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI) using the following format and in line with the Radcliffe reference style:
 

[dataset]* Authors, Year, Title, Publisher (repository or archive name), accession number/DOI * The [dataset] tag will help us identify and tag the correct citation, but this will be removed prior to publication.


We protect an individual's data and will not publish any patient data that might identify an individual without their written consent. For detailed information on our data sharing policy please click here.

4.1 Proofs

All accepted manuscripts will be subject to editorial revisions for clarity, punctuation, syntax and conformity to house style.
 

Laid-out proofs will be sent to the corresponding author following the first stage of editing. Any requests for changes must be returned by the deadline given. Articles are considered final once an author approves the corrected proofs. Only minor changes can be made at the proofing stage; major changes will not be accepted.

4.2 Copyright, Permissions, Open Access and Funding

CCBYNC

Articles published in our Journals are gold open access, which means the version of record (VoR) is freely available, immediately upon publication, without charge, and allows users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

The author retains all non-commercial rights and Radcliffe Medical Media retains all commercial rights (unless otherwise stated) for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license. 

After your manuscript is accepted the corresponding author will be asked to sign a mandatory publishing agreement to grant us permission to publish the manuscript under these terms.

CCBY
From 01 April 2022, we offer the option of publication under the CC-BY 4.0 license for an article publication charge of £1,750 | €2,069 | $2,299 to UK Research Councils (UKRI) and The Wellcome Trust funded authors. Funded authors who wish to use this option to comply with funder mandates must indicate this upon submission by selecting the correct option in the submission system. 

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Evidence will need to be provided for all permissions granted.

After your manuscript is accepted the corresponding author will be asked to sign a mandatory publishing agreement to grant us permission to publish the manuscript under these terms.

Radcliffe General License 
Radcliffe Medical Media retain all rights (unless otherwise stated) for articles that are not published under a creative commons open-access license (pre-2019). Permission to reproduce such an article or any of its contents for commercial purposes, either in full or in part, should be sought from the publication's Managing Editor.

4.3 Author Fees

To support open access publication costs, Radcliffe Cardiology and Radcliffe Vascular charge an Article Publication Charge (APC) to authors upon acceptance of an unsolicited paper, as follows:
 

Content-Type Fee (Non-indexed journal)
Article £1,050 | €1,240 | $1,380
Case Report £787 | €930 | $1,035
Editorial No fee
Expert Opinion £787 | €930 | $1,035
Letter No fee
Meta-analysis £787 | €930 | $1,035

From 01 April 2022, we offer the option of publication under the CC-BY license for UKRI and Wellcome Trust funded submissions. An article publication charge of £1,750 | €2,069 | $2,299 applies. Authors who wish to use this option must indicate this upon submission by selecting the correct funding option in the submission system. 

Members of the Asian Pacific Society of Cardiology will receive a 30% discount on the APC.

Submissions from the UK will be subject to VAT. A VAT registration number should be supplied if applicable. If you are not registered for VAT, your invoice will still have VAT added.
 

After manuscript acceptance, the corresponding author will be contacted, and an invoice will be sent. Accepted articles will not be published until payment has been received.

4.4 APC Waivers and Discounts

A 100% waiver is applicable under the following circumstances:
 

  • For all content solicited by Radcliffe Cardiology/Radcliffe Vascular.
  • For all letters and editorials submitted to the journal.
  • For all content submitted by an editorial board member.
  • If the corresponding author is from a low-income country (as defined by the World Bank). For a full list, see here.


A 50% waiver is applicable under the following circumstances:

  • If the corresponding author is from a lower-middle-income country (as defined by the World Bank). For a full list, see here. 

 

A 30% waiver is applicable under the following circumstances:

  • Society member discounts are available on valid agreements with the publisher for unsolicited content.

 

A 25% waiver is applicable under the following circumstances:

  • If the corresponding author submits a paper within 12 months of completing their most recent peer review for a Radcliffe journal.

 

Discretionary waivers may also be considered.


Radcliffe Cardiology/Radcliffe Vascular remains dedicated to helping researchers to disseminate scientific information globally and is working to partner with individual institutions to offer full or partial APC discounts. If you are an institution looking to partner with us, or think your institution should, then please contact the Publishing Director.


To ensure editorial integrity, the waiver process is not handled by the managing editors. Authors should submit a waiver request during the electronic submission process.

4.5 Misconduct and malpractice

We take reasonable steps to identify and prevent the publication of papers where misconduct has occurred. In no case shall we as the publisher or our editors encourage or knowingly allow such misconduct to take place to published and unpublished papers. 
 

Our journals use similarity checking software to detect unoriginal material and to avoid plagiarism. Where duplication is highlighted, the concerns will be raised with the author.


We do not permit the manipulation of research data through data falsification or data fabrication. Where data falsification or fabrication is suspected, the concerns will be raised with the author.


We reserve the right to reverse decisions to accept a submission where we believe our editorial policies have been infringed and papers suspected of misconduct will not be considered for publication. We reserve the right to inform the author’s co-authors and/or institution/regulatory body when such instances occur.

4.6 Errors, Omissions and Retractions

We take strive to ensure the academic integrity of our journals and to ensure that all content is reproduced correctly. However, we cannot guarantee the accuracy, adequacy or completeness of the information and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Occasionally circumstances may arise were an article is published that must later be retracted or removed. We commit to retract, correct and apologise for any inaccuracies or misleading statements with due prominence through errata which are issued as needed. Any errors should be reported to the journal’s Managing Editor. In all cases, our archives at The British Library and the Agency for Legal Deposit Libraries retain all versions.

4.7 Advertising

Advertising is not permitted to influence editorial decisions. Advertisements cannot be carried by the journal that juxtapose editorial content on the same product. Adverts may appear at the front and back of a journal (never within text). Misleading adverts may be refused. 

4.8 Language and Editing Services

We strongly encourage authors that are non-native Engish speakers to have their manuscripts edited by a native speaker before submitting your article. It will help to improve things like language, grammar, punctuation and clarity and helps peer reviewers to focus on the scientific merits of your work.

We believe that a lack of English language should not be a barrier to publishing high-quality scientific research. Radcliffe will be partnering with a core language editing service provider in the near future but currently recommend the following services:

Charlesworth Author Services
Editage 

4.9 Complaints & Appeals

Any complaints should be first directed to the Editorial Office/Managing Editor of the Journal in writing. If they are the subject of the complaint, please raise this with the Publishing Director. We as the Publisher will aim to deal with any complaints or allegations of misconduct as appropriately and as swiftly as possible. If not resolved satisfactorily, any complaints can be passed to the overseeing body or ombudsmen where one exists. Complaints may be referred to COPES within six months if it cannot be resolved through the journal's complaints procedure and only if it pertains to procedural complaints rather than editorial content.

4.10 Reprints

Reprints of all published articles are available to authors, institutions and commercial organisations. Reprints are published as they appear in the journal unless a correction is to be added. Please contact Rob Barclay at rob.barclay@radcliffe-group.com

5.1 Responsibilities of the Editorial Board

The Editor-in-Chief/Deputy Editor-in-Chief is appointed by the Publisher and/or Society (if a society-owned journal) as an agent and serves at the pleasure of the Publisher/Society. The Editor-in-Chief agrees to assist in a variety of aspects to support the journal, their responsibilities include (but are not limited to):
 

- Supporting the strategic development of the journal.

- Ensuring academic integrity and scientific expertise for the journal.

- Ensuring that accepted content is of the highest possible quality for publication in the journal.

- Making editorial decisions based on the quality and suitability of the journal and not for any political or financial gain.

- Evaluating new submissions to assess their suitability for peer review or immediate rejection, based on journal aims and scope as well as quality standards.

- Deciding on acceptance or rejection following peer review and providing suggestions for revision as appropriate.

- Acting as a final arbiter of the content.

- Suggesting potential authors and proposing titles/topics warranting inclusion or consideration in the journal.

- Ensuring the journal operates ethically and observes the policies set forth herein.

- Providing advice and guidance on editorial board structure and suggesting new members or membership renewal as appropriate.

- Promoting their editorship via appropriate channels to attract high-quality submissions, for example by passively raising the journal’s profile.

- Deputy EiC acting as EiC if required, e.g., for any submissions co-authored by the EiC.

 

Section editors, associate editors, regional editors, and editorial board members benefit the journal by helping to improve turnaround times, increase visibility and submissions and to help expand the scope of a journal. They agree to assist in a variety of aspects of running the journal, their responsibilities include (but are not limited to):
 

- Supporting the journal’s Editor-in-Chief to drive the overall quality of the journal.

- Providing scientific expertise for the journal.

- Submitting one review or expert opinion piece every two years.

- Contributing a minimum of two peer reviews per year on articles they feel qualified to review.

- Promoting the journal to attract high-quality submissions, for example by passively raising the journal’s profile and promoting their board membership where appropriate.

- Providing feedback and suggestions for the journal’s improvement and development.

- Suggesting relevant topics for consideration and potential authors that are within the aims and scope of the journal.

- Attend an annual board meeting so that members can be kept abreast of key journal developments and performance, but this is not compulsory.

 

Editorial Board members are regularly rotated (ideally once every two to three years) and as a Publisher, we encourage diversity in all areas of our editorial boards (nationalities, geographical reach and gender).

Editors-in-Chief, Deputy Editors and Section Editors are selected via an external recruitment and interview process where we would advertise a vacant position on our website and advertise this directly to our cardiovascular community. Editorial Board members are selected based on their activity, knowledge, and research in the field. They should be leaders in research, forward-thinking academics who are reliable and respected in their field and well-positioned to add credit to the journal.

5.2 Soliciting Article Submissions

In order to ensure a strong copy flow, which is critical to ensure the success of a journal, submissions may from time to time be solicited from experts in the field. These are identified in conjunction with the Editor-in-Chief, editorial board and Managing Editor/Publisher to ensure solicited articles are of the highest quality and relevance to the field.

To ensure the journal remains relevant, solicited content is identified based on emerging/hot topics in the field by examining content presented at key conferences that offers new data to the research area, including any important unpublished studies. In addition,  other journal publications are reviewed to identify key trials that may be suitable for summarising their impact on clinical practice in a review article.

For solicited submissions, high-profile, expert authors are identified through publication databases such as Web of Science and Dimensions as well as on recommendation by the Editor-in-Chief, senior editors and editorial board. Authors are solicited based on their research impact (citations, publishing activity, leaders in research, forward-thinking academics and experience within the field). Solicited authors should be reliable and respected in the research community.

Solicited submissions are still always subject to a rigorous double-blind peer-review process.